Traitements futurs de l'insulino-résistance [Insulin resistance treatments in the future].

Details

Serval ID
serval:BIB_AAE1F1EF1031
Type
Article: article from journal or magazin.
Collection
Publications
Title
Traitements futurs de l'insulino-résistance [Insulin resistance treatments in the future].
Journal
Journal de la Société de Biologie
Author(s)
Philippe J., Jornayvaz F.
ISSN
1295-0661 (Print)
ISSN-L
1295-0661
Publication state
Published
Issued date
2007
Peer-reviewed
Oui
Volume
201
Number
2
Pages
155-158
Language
french
Abstract
Present treatment strategies of type 2 diabetes are unsatisfactory. At diagnosis, most oral antidiabetic agents are effective on blood glucose control, but with time metabolic control deteriorates whatever therapeutic modality is used. The reasons for treatment failure are the natural history of the disease and the necessary implication of the patient in the management of blood glucose control on a constant basis. News treatments thus have to be developed acting on either insulin resistance or insulin secretion or both. We discuss here present and future developments which aim to decrease insulin resistance. In the last 10 years, multiple therapeutic targets have been identified in appetite control, such as the endocannabinoid system and glucagon-like-peptide 1, in insulin signalling and in the control of cellular energy balance such as AMP kinase. These developments should allow a better management of type 2 diabetes and its complications.
Keywords
Adenylate Kinase/metabolism, Blood Glucose/metabolism, Diabetes Mellitus, Type 2/physiopathology, Diabetes Mellitus, Type 2/prevention & control, Glucagon-Like Peptides/physiology, Humans, Insulin/secretion, Insulin Resistance/physiology, Kinetics, Receptor, Insulin/physiology, Renin-Angiotensin System, Signal Transduction
Pubmed
Create date
10/09/2015 12:42
Last modification date
20/08/2019 15:14
Usage data